PetVivo Holdings Inc · OTC:PETV
PetVivo — Investor Presentation (July 2023)
22 slides from PetVivo's investor presentation, Jul 21, 2023
Slide 1: Investor Presentation July 2023
Investor Presentation July 2023 PETV (NASDAQ) PetVivo Holdings, Inc.
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and the accompanying oral commentary contains forward-looking statements within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties that could cause actual results to differ materially from those
Slide 3: Company Highlights
Company Highlights a Focus on estimated $11B companion animal veterinary care and product sales market z Spryng™, with our OsteoCushion™ Technology, is a veterinary device that mimics and reinforces articulating cartilage tissue for the management of lameness and other joint- related afflictions inc
Slide 4: Osteoarthritis (OA) Opportunity
Osteoarthritis (OA) Opportunity $11B Veterinary Care and Product Sales Market Osteoarthritis: acommon affliction of the joints * Affects approximately 14 million adult dogs and 1 million horses* * Causes pain and inflammation from degenerated cartilage of stressed joints * Lameness worsens with time
Slide 5: The Optimal OA Solution: Spryng with OsteoCushion Technology
The Optimal OA Solution: Spryng with OsteoCushion Technology * Spryng provides a biocompatible lubricious cushion, which reinforces the cartilage barrier between the bones to protect the remaining cartilage and bone and improve joint function - Similar components/function found in natural cartilage
Slide 6: Spryng with OsteoCushion Technology
Spryng with OsteoCushion Technology * Spryng is a unique new medical device addressing the root cause of the affliction, not just the symptoms * Purified natural components self-assemble to form an insoluble, hydrated matrix - Protein source bovine tissues (i.e. collagen and elastin) from isolated h
Slide 7: Spryng Mechanism of Action
Spryng Mechanism of Action * An animal suffering from osteoarthritis generally exhibits damaged and/or lost cartilage thereby creating bone on bone contact that results in an increase of joint inflammation, pain and further loss of cartilage * Spryng reinforces synovial membrane function, without ph
Slide 8: Spryng Canine Success: Buggy
Spryng Canine Success: Buggy * CONDITION - Buggy is a 13-year-old mixed breed who has led a very active lifestyle. For the last 6 years she has experienced painful mobility, but over the last 2 years her mobility issues have worsened. She commonly trembles with movement. She has not been able to run
Slide 9: Spryng Competitive Distinctions
Spryng Competitive Distinctions ° Outcomes address affliction/not just symptoms i“ Current treatments rely on biologic activity to treat symptoms; Spryng Spryng CANINES provides structural components to address affliction . Price/Cost advantage * Derived from all natural materials “ Ease of applicat
Slide 10: Unique Solution: Spryng and Current Treatments
Unique Solution: Spryng and Current Treatments Cost Polysulfated | Conversion) Hyaluronic . . Product NSAIDs Glycosamino- | Electron ‘Acid | Polyacrylamide) | Joint Injections | Replacement glycan Therapy Injections Temporar —- Reduces | temporan — Total Joint Pro MPOTGLY | inflammation; Pain| synov
Slide 11: Exclusive Distribution Services Agreement
Exclusive Distribution Services Agreement AmerisourceBergen ty SPLYND’ MWI Animal Health® with OsteoCushion” Technology MWI - PetVivo Distribution Services Agreement Terms: + Two years of exclusivity with option for third year upon achieving mutually agreed upon milestones + Transition to non-exclus
Slide 12: Spryng Clinical Trials
Spryng Clinical Trials EQUINE * OKLAHOMA CITY EQUINE — Equine Tolerance Study + Principal investigator = Oklahoma City Equine Clinic, P.C. (CEC), Dr. Brian S. Carroll, DVM and OCEC staff veterinarians + Study Design = Equine Tolerance Study, 21 horse blinded study + Completed = December 2021 SMALL A
Slide 13: Spryng Clinical Trials
Spryng Clinical Trials SMALL ANIMAL * ETHOS * Principal investigators * Chand Khanna, DVM, PhD, DACVIM, DACVP, Samuel Stewart, DVM, DACVECC, and Chris Thomson, DVM, DACVS-SA * Study design — Pilot study to evaluate the intra- articular injection of Spryng in dogs with stifle disease with initial pro
Slide 14: Production Facilities
Production Facilities Spryng product is manufactured in PetVivo’s ISO certified cleanrooms (ISO 8 to ISO 7 to ISO 5) Current production facility annual capacity is sufficient to satisfy projected annual supply needs for at least five years A second manufacturing facility is expected to be operationa
Slide 15: Comprehensive IP Portfolio US Patents and Foreign Patents
Comprehensive IP Portfolio 10 US Patents and 9 Foreign Patents Broad Claim Language - “Comprising” Transitions Our Patents & Trade Secrets Protect: * Protein & Carbohydrate Based Thermoplastics * Biomaterials of Many Compositions ¢ Medical, Drug Delivery & Combination Products * Medical & Pharmaceut
Slide 16: Pet Product Pipeline (FDA clearance not required)
Pet Product Pipeline (FDA clearance not required) Pet Therapeutics Species Efficacy Commercial VD-01 |Osteoarthritis Canine (Spryng™) VD-02 |Osteoarthritis Equine (Spryng™) VD-03 Digital Cushion Lameness. Equine VD-04 | Urinary Incontinence Canine \VD-06 | Osteoarthritis Feline (Spryng'™) VD-07 |Muc
Slide 17: Market Overview: Companion Animal/Veterinarian
Market Overview: Companion Animal/Veterinarian US Pet Spend increased from $103.6B in 2020 to $123.6B in 2021 . * Veterinary care and products is a leading growth driver - $11B in 2021 in US 70% of US Households own a pet - 83.0M Dogs; 45.3M Cats Approximately 7.2M horses in US* . Pet owners’ spendi
Slide 18: Management Team
Management Team * John Lai, Chief Executive Officer, Blue Earth Resources, Genesis Capital Group * Robert J. Folkes, Chief Financial Officer, Tactile Medical, Advanced Respiratory * Randall Meyer, Chief Operating Officer, Ge/-Del Tech, Softscope Medical, Tactile Medical * John F. Dolan, Vice Preside
Slide 19: Board of Directors and Advisors
Board of Directors and Advisors Board of Directors James Martin, Board Chairman, KPMG LLP (Partner; Retired) Joseph Jasper, Vermillion Capital Management, Piper Jaffray Robert Rudelius, Noble Ventures LLC, MedicaMetrix, Inc. Leslie Coolidge, Power Solutions International, Inc., KPMG LLP (Partner; Re
Slide 20: Growth Drivers
Growth Drivers * Expand Sales Force and Distribution ¢ Add regional sales managers * Distributor networks . Vetcove @)(Dec. 2021) * MWIDSA (June 2022) * Increase KOL Adoption * Used by veterinarians in more than 450 clinics in 47 states * Podium presentations at conferences * Increase Market Awarene
Slide 21: PetVivo Highlights
PetVivo Highlights Tt Large market opportunity - $11B Veterinary Care and Products Market and growing 2 Increased humanization of companion animals driven by Covid-19 pandemic Spryng is an optimal solution for the management of OA over the current treatments Offers significant benefits for the manag
Slide 22: John Lai
John Lai Chief Executive Officer lai@petvivo.com (612) 328-4325 PetVivo.com To order, contact infol@petvive.com or 844-PET-VIVO (844-738-8486) sSpryngt with OsteoCusion™ Technologyis a ‘elatinary meckcalcevice by PetVivo, Ine Sponattisa kaclemenk of PetVivo Holdings, ne This produc! iscovered by US.